Bath scientists stabilise vaccine proteins with ensilication
A new system for delivering vaccines to children in low-income nations has taken a vital step forward, thanks to groundbreaking work at the University of Bath
Vaccines are notoriously difficult to transport to remote or dangerous places, as they spoil when not refrigerated. Formulations are safe between 2°C and 8°C, but at other temperatures the proteins start to unravel, making the vaccines ineffective. As a result, millions of children around the world miss out on life-saving inoculations.
However, scientists have now found a way to prevent warmed-up vaccines from degrading. By encasing protein molecules in a silica shell, the structure remains intact even when heated to 100°C, or stored at room temperature for up to three years.
The technique for tailor-fitting a vaccine with a silica coat – known as ensilication – was developed by a Bath team in collaboration with the University of Newcastle. This pioneering technology was seen to work in the lab two years ago, and now it has demonstrated its effectiveness in the real world too.
The researchers explain the significance of their findings
In their latest study, published in the journal Scientific Reports, the researchers sent both ensilicated and regular samples of the tetanus vaccine from Bath to Newcastle by ordinary post (a journey time of over 300 miles, which by post takes a day or two). When doses of the ensilicated vaccine were subsequently injected into mice, an immune response was triggered, showing the vaccine to be active. No immune response was detected in mice injected with unprotected doses of the vaccine, indicating the medicine had been damaged in transit.
Dr Asel Sartbaeva, who led the project from the University of Bath’s Department of Chemistry, said: “This is really exciting data because it shows us that ensilication preserves not just the structure of the vaccine proteins but also the function – the immunogenicity.”
“This project has focused on tetanus, which is part of the DTP (diphtheria, tetanus and pertussis) vaccine given to young children in three doses. Next, we will be working on developing a thermally-stable vaccine for diphtheria, and then pertussis. Eventually we want to create a silica cage for the whole DTP trivalent vaccine, so that every child in the world can be given DTP without having to rely on cold chain distribution.”
Cold chain distribution requires a vaccine to be refrigerated from the moment of manufacturing to the endpoint destination.
Silica is an inorganic, non-toxic material, and Dr Sartbaeva estimates that ensilicated vaccines could be used for humans within five to 15 years. She hopes the technology to silica-wrap proteins will eventually be adopted to store and transport all childhood vaccines, as well as other protein-based products, such as antibodies and enzymes.
“Ultimately, we want to make important medicines stable so they can be more widely available,” she said. “The aim is to eradicate vaccine-preventable diseases in low income countries by using thermally stable vaccines and cutting out dependence on cold chain.”
Currently, up to 50% of vaccine doses are discarded before use due to exposure to suboptimal temperatures. According to the World Health Organisation (WHO), 19.4 million infants did not receive routine life-saving vaccinations in 2018.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Vaccines
- Barking good time: Dog Days in May offers free vaccines for dogs
Dog lovers gathered in Belpre Saturday for the annual Dog Days in May event. The Humane Society of the Ohio Valley (HSOV) hosted its annual Dog Days in May at Howes Grove Park in Belpre. According to ...
- Novavax, Sanofi enter licensing agreement to co-commercialize Covid-19 vaccine and develop novel Covid-19-influenza combination vaccines
Gaithersburg, Maryland Monday, May 13, 2024, 11:00 Hrs [IST] ...
- Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy?
The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could soon provide more-robust data about candidates’ efficacy and safety.
- Groups seek free anti-flu vaccines for senior citizens
An alliance of welfare groups presses the government to provide free flu vaccines to seniors citizens While the government had increased senior citizen discounts on basic goods, the welfare groups ...
- Low Risk for New-Onset Thyroid Diseases After mRNA Vaccines
There were 77 cases of thyroid-related autoimmune diseases among people with no history of an autoimmune disease prior to receiving the COVID-19 vaccine, with 38 cases of Graves' disease (GD) and 39 ...
Go deeper with Google Headlines on:
Vaccines
[google_news title=”” keyword=”vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Thermally-stable vaccine
- USM Graduate School holds annual Susan A. Siltanen Graduate Student Research Symposium
USM graduate students were recognized for their research at The University of Southern Mississippi (USM) Graduate School’s annual Susan A. Siltanen Graduate Student Research Symposium held in April on ...
- The Egg and I: Could Today’s Bird Flu Be Tomorrow’s COVID?
The bird-flu (highly pathogenic form of avian influenza) outbreaks are wreaking havoc on laying flocks of leghorns (white eggs) and Rhode Island reds (brown eggs) after being exposed to the virus ...
- Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa
Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa: Princeton, New Jersey Saturday, April 27, 2024, 11:00 Hrs [IST] Soligenix, Inc, a ...
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization "Our next generation combined vaccine platform includes three major ...
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Under the Company's Public Health Solutions business segment, ongoing collaborations with Dr. Lehrer, have demonstrated the feasibility of developing thermally-stable subunit protein vaccine ...
Go deeper with Google Headlines on:
Thermally-stable vaccine
[google_news title=”” keyword=”thermally-stable vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]